Novartis CEO Sees China Sales Growth In Innovative Drugs, Not Generics
This article was originally published in PharmAsia News
Novartis CEO Joseph Jimenez is banking on China sales to help carry the Swiss-based firm through a transition period during which it loses patent protection for some of its most successful products
You may also be interested in...
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
Smiths Medical is increasing paraPAC ventilator production from hundreds to thousands a month to fulfill 10,000 units as part of the Ventilator Challenge UK consortium.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.